Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab and Verteporfin Combination in nAMD
NCT00967213Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2006
- Primary completion
- Feb 2008
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab, verteporfin in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Aug 2006; status: completed.
02
Drugs
ranibizumabverteporfin
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00967213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00967213.